LivaNova PLC
Open
$59.36
Prev. Close
$59.36
High
$59.37
Low
$59.35
Market Snapshot
$3.22B
-13.3
1.16
$1.25B
LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. The firm designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
emptyResult
LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. The firm designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
Recently from Cashu
LivaNova PLC Reports Strong Q4 Growth, Highlighting Innovation and Market Opportunities
LivaNova's Strong Q4 Performance Signals Innovation and Growth Potential LivaNova PLC announces significant progress with its Q4 earnings, showcasing a robust growth trajectory pivotal to its role in…
LivaNova PLC's Q4 2025: Strong Growth in Neuromodulation and Cardiopulmonary Segments
LivaNova's Strategic Growth in Neuromodulation and Cardiopulmonary Segments LivaNova PLC showcases significant financial progress in its recent Q4 2025 earnings report, highlighting a solid foundation…
LivaNova Reports Strong Q4 2025 Earnings, Boosting Market Position and Innovation Focus
LivaNova Reports Impressive Q4 2025 Earnings, Enhancing Market Position LivaNova PLC reveals its Q4 2025 earnings on February 25, 2026, showcasing a robust performance that underscores the company’s s…
LivaNova PLC: Innovating Medical Technologies for Enhanced Patient Care and Outcomes
LivaNova PLC: Pioneering Innovations in Medical Technologies LivaNova PLC continues to make significant strides in the medical device industry, focusing on innovative therapies to enhance patient care…